Linezolid is the first of a new class of antibiotics with a unique mechanism of action against Methicillin-Resistant Staphylococcus Aureus (MRSA). This is a Phase IV, double-blinded, randomized study for patients with hospital acquired pneumonia proven to be caused by MRSA. Patients will be treated with linezolid or vancomycin for a minimum of 7 days and up to a maximum of 14 days. The primary objective of this study is to compare the clinical efficacy of linezolid to vancomycin in treatment of pneumonia due to MRSA.

Condition	Treatment or Intervention	Phase
Pneumonia	Drug: Linezolid  Drug: Vancomycin	Phase IV

Further Study Details: 

Expected Total Enrollment:  1200

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

• Hospitalized adults aged 18 years or older
• Hospital acquired pneumonia (acquired 48 hours after hospitalization)
• Chest X-ray or CT scan consistent with the diagnosis of pneumonia
• Subjects with severe neutropenia (<500 cells/mm3) are excluded
• Subjects with hypersensitivity to linezolid or vancomycin are excluded

Call:      1-734-622-7600    ClinicalTrials.gov@Pfizer.com

Alabama
      Pfizer Investigational Site, Montgomery,  Alabama,  36111,  United States; Recruiting
      Pfizer Investigational Site, Montgomery,  Alabama,  36116,  United States; Recruiting
Arizona
      Pfizer Investigational Site, Phoenix,  Arizona,  85008,  United States; Recruiting
California
      Pfizer Investigational Site, Redlands,  California,  92373,  United States; Recruiting
      Pfizer Investigational Site, Los Angeles,  California,  90033,  United States; Recruiting
District of Columbia
      Pfizer Investigational Site, Washington,  District of Columbia,  20037,  United States; Recruiting
Florida
      Pfizer Investigational Site, Clearwater,  Florida,  33756,  United States; Recruiting
      Pfizer Investigational Site, Atlantis,  Florida,  33462,  United States; Recruiting
      Pfizer Investigational Site, Clearwater,  Florida,  33756,  United States; Recruiting
      Pfizer Investigational Site, Tampa,  Florida,  33607,  United States; Recruiting
      Pfizer Investigational Site, Miami,  Florida,  33136,  United States; Recruiting
Georgia
      Pfizer Investigational Site, Augusta,  Georgia,  30909,  United States; Recruiting
      Pfizer Investigational Site, Augusta,  Georgia,  30912,  United States; Recruiting
Illinois
      Pfizer Investigational Site, Springfield,  Illinois,  62703,  United States; Recruiting
      Pfizer Investigational Site, Springfield,  Illinois,  62701,  United States; Recruiting
      Pfizer Investigational Site, Springfield,  Illinois,  62702,  United States; Recruiting
Indiana
      Pfizer Investigational Site, Indianapolis,  Indiana,  46202,  United States; Recruiting
Kentucky
      Pfizer Investigational Site, Louisville,  Kentucky,  40206,  United States; Recruiting
Maryland
      Pfizer Investigational Site, Baltimore,  Maryland,  21201,  United States; Recruiting
Massachusetts
      Pfizer Investigational Site, Boston,  Massachusetts,  02111,  United States; Recruiting
      Pfizer Investigational Site, Springfield,  Massachusetts,  01199,  United States; Recruiting
Michigan
      Pfizer Investigational Site, Detroit,  Michigan,  48201,  United States; Recruiting
      Pfizer Investigational Site, Detroit,  Michigan,  48210,  United States; Recruiting
      Pfizer Investigational Site, Detroit,  Michigan,  48202,  United States; Recruiting
      Pfizer Investigational Site, Detroit,  Michigan,  48201,  United States; Recruiting
Missouri
      Pfizer Investigational Site, Springfield,  Missouri,  65807,  United States; Recruiting
      Pfizer Investigational Site, Springfield,  Missouri,  65804,  United States; Recruiting
      Pfizer Investigational Site, St. Louis,  Missouri,  63110,  United States; Recruiting
      Pfizer Investigational Site, Springfield,  Missouri,  65804,  United States; Recruiting
New York
      Pfizer Investigational Site, Bronx,  New York,  10467,  United States; Recruiting
      Pfizer Investigational Site, Buffalo,  New York,  14215,  United States; Recruiting
      Pfizer Investigational Site, New York,  New York,  10021,  United States; Recruiting
      Pfizer Investigational Site, Albany,  New York,  12208,  United States; Recruiting
      Pfizer Investigational Site, Rochester,  New York,  14642,  United States; Recruiting
      Pfizer Investigational Site, Brooklyn,  New York,  11215,  United States; Recruiting
North Carolina
      Pfizer Investigational Site, Greensboro,  North Carolina,  27401,  United States; Recruiting
      Pfizer Investigational Site, Greenville,  North Carolina,  27834,  United States; Recruiting
      Pfizer Investigational Site, Greensboro,  North Carolina,  27401,  United States; Recruiting
Ohio
      Pfizer Investigational Site, Toledo,  Ohio,  43614,  United States; Recruiting
Oregon
      Pfizer Investigational Site, Portland,  Oregon,  97213,  United States; Recruiting
Pennsylvania
      Pfizer Investigational Site, Allentown,  Pennsylvania,  18103,  United States; Recruiting
      Pfizer Investigational Site, Philadelphia,  Pennsylvania,  19140,  United States; Recruiting
      Pfizer Investigational Site, Philadelphia,  Pennsylvania,  19107,  United States; Recruiting
South Dakota
      Pfizer Investigational Site, Sioux Falls,  South Dakota,  57117,  United States; Recruiting
      Pfizer Investigational Site, Sioux Falls,  South Dakota,  57104,  United States; Recruiting
      Pfizer Investigational Site, Sioux Falls,  South Dakota,  57105,  United States; Recruiting
Tennessee
      Pfizer Investigational Site, Nashville,  Tennessee,  37232,  United States; Recruiting
      Pfizer Investigational Site, Jackson,  Tennessee,  38301,  United States; Recruiting
Texas
      Pfizer Investigational Site, San Marcos,  Texas,  78666,  United States; Recruiting
      Pfizer Investigational Site, Sequin,  Texas,  78155,  United States; Recruiting
Chile
      Pfizer Investigational Site, Santiago,  Chile; Recruiting
Colombia, Bogota DC
      Pfizer Investigational Site, Bogota,  Bogota DC,  Colombia; Recruiting
Puerto Rico
      Pfizer Investigational Site, San Juan,  00921,  Puerto Rico; Recruiting

Study ID Numbers:  A5951001
Record last reviewed:  March 2005
Last Updated:  March 15, 2005
Record first received:  June 9, 2004
ClinicalTrials.gov Identifier:  NCT00084266
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08